The pharmaceutical company plans to invest $30 billion in the US over the next 5 years, including a new $1.2 billion facility, to strengthen its R&D and manufacturing capabilities.
The major pharmaceutical company has announced the acquisition of ordinary shares by several of its directors and senior managers under an employee share plan.
The healthcare company has announced a share award to a senior executive under its 2025 Share Value Plan.
The healthcare company has announced a director/PDMR shareholding transaction.
The healthcare company has disclosed changes to director and PDMR shareholdings through dividend reinvestment.
The major pharmaceutical company's directors have acquired ordinary shares under the company's employee share plan.
The healthcare company announced the FDA has accepted for priority review its application for gepotidacin, an oral antibiotic, to treat uncomplicated urogenital gonorrhea.
The healthcare company has reached a settlement with CureVac and BioNTech over mRNA patent litigation, securing an upfront payment and future royalties.
The pharmaceutical giant has raised its full-year guidance following strong H1 results, with significant profit growth and improved cash generation across key business segments.
The pharmaceutical company has entered a collaboration agreement to develop up to 12 innovative medicines, adding significant new growth opportunities.